Skip to main content

CORRECTION article

Front. Oncol., 14 April 2021
Sec. Cancer Molecular Targets and Therapeutics

Corrigendum: Identification of a Two-Gene (PML-EPB41) Signature With Independent Prognostic Value in Osteosarcoma

\nShengye LiuShengye Liu1Jiamei LiuJiamei Liu2Xuechen YuXuechen Yu3Tao Shen
Tao Shen1*Qin Fu
Qin Fu1*
  • 1Department of Spine and Joint Surgery, Shengjing Hospital of China Medical University, Shenyang, China
  • 2Department of Pathology, Shengjing Hospital of China Medical University, Shenyang, China
  • 3Hammer Health Sciences Center, Columbia University Medical Center, New York, NY, United States

A Corrigendum on
Identification of a Two-Gene (PML-EPB41) Signature With Independent Prognostic Value in Osteosarcoma

by Liu, S., Liu, J., Yu, X., Shen, T., and Fu, Q. (2020). Front. Oncol. 9:1578. doi: 10.3389/fonc.2019.01578

In the original article, there was an error. Dataset GSE39058 was miswritten as GSE39055, 42 samples was miswritten as 47.

A correction has been made to RESULTS, Identification of Seed Genes Based on the Coefficient of Variation in OSA, 1:

In the present study, we established a 2-gene signature for the prognostic prediction of OSA (Figure 1). First, we used the GSE39058 dataset, which included 47 samples, as a training set. In this dataset, each patient sample included detailed clinicopathologic information and survival status. The coefficient of variation (CV) of each probe was calculated for all samples, and the probes with a CV >20% were considered to have the largest degree of variation among all OSA samples and were selected as the seed probes. Then, 309 probes were obtained and mapped to 308 unique genes. Next, we completed an unsupervised clustering analysis of the 42 samples by using expression profiling of the 309 probes obtained in the previous step. As shown in Figure 2A, the OSA samples were divided into 2 groups, and there were significant differences in gene expression levels between the groups. Survival analysis was then used to compare the outcomes of the groups: no significant difference was observed between them (log-rank test p ≥ 0.05) (Figure 2B).

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Keywords: osteosarcoma, protein-protein interaction network, gene signature, prognostic prediction, survival analysis

Citation: Liu S, Liu J, Yu X, Shen T and Fu Q (2021) Corrigendum: Identification of a Two-Gene (PML-EPB41) Signature With Independent Prognostic Value in Osteosarcoma. Front. Oncol. 11:671129. doi: 10.3389/fonc.2021.671129

Received: 23 February 2021; Accepted: 24 February 2021;
Published: 14 April 2021.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2021 Liu, Liu, Yu, Shen and Fu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Tao Shen, Y211X3NoZW50YW8mI3gwMDA0MDsxNjMuY29t; Qin Fu, Y211X2Z1cWluJiN4MDAwNDA7MTYzLmNvbQ==

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.